Puromycin Aminonucleoside: Benchmark Nephrotoxic Agent for Podocyte Injury Models

Executive Summary: Puromycin aminonucleoside (CAS 58-60-6) is a well-characterized aminonucleoside derived from puromycin, primarily used to induce nephrotic syndrome in animal models via targeted podocyte injury (ApexBio A3740). It disrupts podocyte microvilli and foot-process structures, leading to proteinuria and glomerular lesions that closely mimic human focal segmental glomerulosclerosis (FSGS) (Meng et al., 2017). Its cytotoxicity and uptake are quantitatively defined in MDCK cell models, with IC50 values dependent on transporter expression and extracellular pH. Puromycin aminonucleoside is highly soluble in DMSO, ethanol, and water under specific conditions, and requires storage at −20°C for optimal stability. Its use as a reference nephrotoxic agent underpins preclinical research into proteinuria, renal function impairment, and the pathophysiology of nephrotic syndrome.

Biological Rationale

Puromycin aminonucleoside is the aminonucleoside moiety of puromycin, an antibiotic originally isolated from Streptomyces alboniger. In experimental nephrology, it serves as a prototypical nephrotoxic agent for modeling glomerular injury leading to nephrotic syndrome. The compound specifically targets podocytes, which are specialized epithelial cells forming the glomerular filtration barrier. Podocyte injury is central to the development of proteinuria and glomerular lesions in several human renal diseases, including FSGS. Animal models employing puromycin aminonucleoside recapitulate key features of these syndromes—namely, selective podocyte effacement, proteinuria, and lipid accumulation in glomerular cells (ApexBio).

Mechanism of Action of Puromycin aminonucleoside

Puromycin aminonucleoside exerts its nephrotoxic effects by altering the morphology and function of podocytes. In vitro, it induces rapid reductions in microvilli density and disrupts foot-process architecture—critical for the filtration function of the glomerulus. These structural changes are associated with increased permeability of the glomerular filtration barrier, leading to significant proteinuria. In vivo, administration in rats produces glomerular lesions that morphologically and functionally resemble human FSGS (Meng et al., 2017).

Cellular uptake of puromycin aminonucleoside is enhanced in cells expressing the plasma membrane monoamine transporter (PMAT), especially under acidic conditions (pH 6.6). Quantitatively, the compound displays cytotoxicity in MDCK cells with IC50 values of 48.9 ± 2.8 μM (vector) and 122.1 ± 14.5 μM (PMAT-transfected) (ApexBio).

Evidence & Benchmarks

• Puromycin aminonucleoside administration in rats induces proteinuria and segmental glomerular lesions within 7–10 days, modeling human FSGS pathophysiology (Meng et al., 2017).
• Electron microscopy shows loss of podocyte microvilli and effacement of foot processes after exposure (Puromycin Aminonucleoside: Precision Modeling for Nephrot...).
• In vitro, IC50 values for cytotoxicity are 48.9 ± 2.8 μM in vector MDCK cells and 122.1 ± 14.5 μM in PMAT-expressing cells at pH 7.4 (ApexBio).
• Solubility is ≥14.45 mg/mL in DMSO, ≥29.4 mg/mL in ethanol, and ≥29.5 mg/mL in water (with gentle warming), facilitating diverse experimental protocols (ApexBio).
• Short-term solution stability is optimal at −20°C; longer-term storage or repeated freeze-thaw cycles reduce compound efficacy (ApexBio).

This article expands upon the mechanistic and translational focus in Puromycin Aminonucleoside: Mechanistic Precision and Strategy by providing granular quantitative benchmarks and clarifying experimental pitfalls. For advanced troubleshooting and experimental design, see Precision Podocyte Injury for Proteinuria Models, which this article updates with new IC50 and solubility data.

Applications, Limits & Misconceptions

Puromycin aminonucleoside is widely used for:

• Inducing proteinuria and podocyte injury in rodent models of nephrotic syndrome.
• Modeling glomerular lesions typical of FSGS and minimal change disease.
• Evaluating candidate nephroprotective compounds and studying renal pathophysiology.
• Quantifying transporter-mediated cytotoxicity and uptake in renal epithelial cell lines.

However, the compound has well-defined boundaries:

Common Pitfalls or Misconceptions

• It does not replicate immune-mediated glomerulonephritis or all features of human nephrotic syndrome.
• High inter-strain variability in susceptibility exists among rodent models.
• Chronic administration may induce off-target toxicity not representative of human disease.
• It is not suitable for modeling tubular, interstitial, or vascular renal injuries.
• Repeated freeze-thawing or storage above −20°C degrades compound stability and efficacy.

Workflow Integration & Parameters

Experimental use involves intravenous or subcutaneous administration in rats, with typical dosages ranging from 50–150 mg/kg, depending on the desired severity of nephrosis. Solutions are freshly prepared in water (≥29.5 mg/mL with gentle warming) or DMSO (≥14.45 mg/mL), filtered, and used within a short time frame to preserve chemical integrity. Readouts include measurement of urinary protein excretion, histological analysis of glomerular lesions, and quantification of nephrin or other podocyte marker expression. When testing transporter-mediated uptake, pH and PMAT expression must be controlled (ApexBio).

For troubleshooting and workflow optimization, see Redefining Translational Nephrology: Mechanistic Nuance and Impact, which is complemented by the present article's detailed experimental parameterization.

Conclusion & Outlook

Puromycin aminonucleoside (A3740) remains the gold standard for mechanistic and preclinical modeling of podocyte injury, proteinuria, and FSGS in nephrology research. Its quantitative uptake, cytotoxicity, and solubility parameters enable reproducible workflows and robust experimental design. Ongoing advances in transporter biology and renal cell modeling will likely expand the compound’s utility in dissecting glomerular pathomechanisms and evaluating novel therapeutics (Meng et al., 2017).

For ordering and lot-specific documentation, visit the Puromycin aminonucleoside product page.